FDA approves Roche's Gazyva as first specifically authorised treatment for primary membranous nephropathy

The FDA has approved Roche's Gazyva for primary membranous nephropathy, establishing the first specifically authorised treatment for the condition after Phase III evidence demonstrated substantially higher complete proteinuria remission rates than tacrolimus.
Roche announced on 16 November 2026 that the US Food and Drug Administration had approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy who are at risk of disease progression, providing the first medicine specifically authorised to induce remission of proteinuria in this autoimmune kidney disorder.
In the Phase III MAJESTY trial, approximately 36% of patients receiving Gazyva achieved complete proteinuria remission at week 104 compared with approximately 6% receiving tacrolimus, while the medicine's existing boxed warnings include hepatitis B reactivation and progressive multifocal leukoencephalopathy; this is a new indication for an already authorised medicine rather than obinutuzumab's first FDA approval.
Field | Content |
Article Type | Approvals |
Company | Roche |
Product Brand Name | Gazyva |
Active Ingredient | Obinutuzumab |
Drug Classification | Anti-CD20 monoclonal antibody |
Regulatory Authority | US Food and Drug Administration |
Announcement Date | 16 November 2026 |
Regulatory Decision | New indication approval |
Geographic Scope | United States |
Therapeutic Area | Nephrology |
Disease | Primary membranous nephropathy |
Disease Classification | Autoimmune kidney disorder |
Approved Population | Adults with primary membranous nephropathy at risk of disease progression |
Treatment Objective | Induction of proteinuria remission |
First FDA-Approved Treatment for Condition | Yes |
Existing Product | Gazyva was previously approved for other indications |
Supporting Clinical Trial | MAJESTY |
Clinical Trial Phase | Phase III |
Key Efficacy Measure | Complete proteinuria remission |
Assessment Time Point | Week 104 |
Gazyva Complete Remission Rate | Approximately 36% |
Comparator | Tacrolimus |
Comparator Complete Remission Rate | Approximately 6% |
Approximate Absolute Remission Difference | 30 percentage points |
Boxed Warning One | Hepatitis B virus reactivation |
Boxed Warning Two | Progressive multifocal leukoencephalopathy |
What Happened | The FDA approved obinutuzumab for adults with primary membranous nephropathy at risk of progression. |
Why It Matters | The decision establishes the first specifically authorised pharmacological treatment for a condition previously managed without an FDA-approved disease-specific medicine. |
Clinical Significance | The MAJESTY study demonstrated higher complete proteinuria remission rates with Gazyva than with tacrolimus at week 104. |
Regulatory Significance | Expands an existing medicine into a new nephrology indication. |
Safety Significance | The treatment carries serious infection-related boxed warnings requiring appropriate clinical precautions. |
Key Takeaway | Gazyva is now the first FDA-approved medicine specifically for primary membranous nephropathy. |
What to Watch | Treatment uptake, nephrology guidelines, reimbursement, long-term kidney outcomes and real-world safety. |
Primary Source | US Food and Drug Administration |
Primary Source URL | https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy |
Submitted Source | GeneOnline |
Submitted Source URL | https://www.geneonline.com/gazyva-becomes-first-fda-approved-treatment-for-primary-membranous-nephropathy-after-years-of-off-label-care/ |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments